导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.60% | 2964/4773 |
| 近一周 | -2.38% | 2014/5462 |
| 近一月 | -2.17% | 1189/5421 |
| 近一季 | -1.64% | 1038/5209 |
| 近半年 | -0.37% | 1283/4920 |
| 近一年 | -1.39% | 2867/4366 |
| 近两年 | 52.01% | 1421/2954 |
| 近三年 | 36.20% | 824/2253 |
| 成立以来 | 42.06% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-6.31% 4093/4961 |
4.81% 2903/5312 |
- - |
- - |
| 2025 | 25.37% 1716/4813 |
-0.11% 2062/3635 |
4.16% 844/4076 |
20.21% 2012/4524 |
0.24% 2103/4813 |
| 2024 | 21.49% 413/3463 |
5.08% 405/2808 |
-2.32% 1176/3014 |
18.31% 1026/3129 |
0.05% 1280/3463 |
| 2023 | -10.07% 1261/2656 |
1.07% 1649/2280 |
-7.39% 1848/2385 |
3.99% 163/2515 |
-7.61% 2178/2655 |
| 2022 | -17.61% 610/2207 |
-12.98% 679/1919 |
7.46% 471/2016 |
-15.84% 1351/2113 |
4.69% 521/2208 |
| 2021 | -7.35% 1036/1822 |
-1.16% 441/1255 |
-1.81% 1178/1330 |
-5.90% 876/1466 |
1.45% 925/1822 |
| 2020 | 22.42% 672/1250 |
-8.90% 638/1028 |
6.70% 856/1067 |
13.26% 330/1164 |
11.20% 555/1184 |
| 2019 | 29.72% 496/1092 |
19.33% 627/754 |
-0.30% 248/804 |
-0.62% 603/850 |
9.72% 204/918 |
| 2018 | -16.03% 104/834 |
- - |
- - |
- - |
-11.76% 346/691 |
| 2017 | 20.72% 178/714 |
- - |
- - |
- - |
- - |
| 2016 | 1.91% 90/605 |
- - |
- - |
- - |
- - |
| 2015 | -1.06% 261/575 |
- - |
- - |
- - |
- - |
| 2014 | 51.40% 75/237 |
- - |
- - |
- - |
- - |
| 2013 | -21.18% 177/186 |
- - |
- - |
- - |
- - |
| 2012 | 17.28% 6/140 |
- - |
- - |
- - |
- - |
| 2011 | -18.28% 22/102 |
- - |
- - |
- - |
- - |
| 2010 | -25.58% 57/58 |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 博时上证超大盘ETF VS. 长安沪深300非周期A(740101) |